Glioma, Malignant
72
19
28
14
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.7%
7 terminated out of 72 trials
66.7%
-19.9% vs benchmark
1%
1 trials in Phase 3/4
14%
2 of 14 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 14 completed trials
Clinical Trials (72)
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile®
Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma
A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor
Niraparib In Recurrent IDH 1/2 Gliomas
Imaging of Solid Tumors Using 18F-TRX
Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma
Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma
GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM
Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
Window of Opportunity Study of DSP-0390 in Gliomas
ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients